A Phase 3 interventional study of Aprepitant Injection and Aprepitant Injection Placebo in Post-operative Nausea and Vomiting (PONV), sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 15 in phase 3, and was the 60th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 486 is above the median of 103 across 674 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 29 studies on the registry; 20 are open to participants now.
CSPC Pharmaceutical Group Limited has 1 study filed under Vomiting — fewer than ten, so there is no comparison to draw.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,
In this study, a randomized, double-blind, placebo-controlled multicenter study will be conducted to evaluate the efficacy and safety of aprepitant injection in the prevention of post-operative nausea and vomiting (PONV).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥18 and ≤75 years old; 18 \< ≤30kg/m\^2, body weight ≥45kg; laparoscopic gynecologic or abdominal surgery under general anesthesia that was expected to last at least 1 hour.
expected or agreed to stay in the hospital for 24 hours or more after surgery;
Exclusion Criteria:
diagnostic surgery; scheduled for postoperative transfer to an intensive care unit; requiring placement of a nasogastric or orogastric tube after surgery; Post-operative vomiting may pose significant risk;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before anesthesia induction, 4.4ml(32mg) was given by a single intravenous injection, which was completed within 30 seconds
Drug: Aprepitant Injection
Before anesthesia induction, 4.4ml(0mg)was given by a single intravenous injection, which was completed within 30 seconds
Drug: Aprepitant Injection Placebo
Before anesthesia induction, 4.4ml(32mg) was given by a single intravenous injection, which was completed within 30 seconds
Before anesthesia induction, 4.4ml(0mg) was given by a single intravenous injection, which was completed within 30 seconds
Complete response (CR) rates over 24 hours after the end of surgery
Complete response (defined as no emetic episodes and no use of rescue therapy)
Time frame: 0-24 hours after the end of surgery
Proportion of participants who have no nausea in the 0 to 24 hours following the end of surgery
No nausea(defined as a visual analogue scale (VAS) nausea score \< 1.)
Time frame: 0-24 hours after the end of surgery
Proportion of participants who have significant nausea in the 0 to 24 hours following the end of surgery
Significant nausea(defined as a visual analogue scale (VAS) nausea score≥4)
Time frame: 0-24 hours after the end of surgery
Proportion of participants who have no vomiting or retching in the 0 to 24 hours following the end of surgery
No vomiting or retching(Defined as whether or not use remedy treatment had no vomiting)
Time frame: 0-24 hours after the end of surgery
Proportion of participants who use the remedial treatment in the 0 to 24 hours following the end of surgery
Time frame: 0-24 hours after the end of surgery
Time to treatment failure in the 0 to 24 hours following the end of surgery
defined as the time to the first episode of vomiting (vomiting or retching) or the time to rescue therapy, whichever occurred first.
Time frame: 0-24 hours after the end of surgery
Proportion of participants who have no vomiting or retching in the 0 to 48 hours following the end of surgery
No vomiting or retching(Defined as whether or not use remedy treatment had no vomiting)
Time frame: 0-48 hours after the end of surgery
The time to the first episode of vomiting (vomiting or retching) in the 0 to 48 hours following the end of surgery
Time frame: 0-48 hours after the end of surgery
Number of participants with treatment-related adverse events as assessed by NIH
Safety was assessed by Adverse events (AEs) were recorded after administration.
Time frame: Day 0 to Day14
No study locations are listed for this record.
Start is estimated for Oct 2024; primary completion for Mar 2026, 17 months later.
Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aprepitant
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. →